These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 7678882

  • 1. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
    Gunther R, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Uckun FM.
    Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
    [Abstract] [Full Text] [Related]

  • 2. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Jansen B, Kersey JH, Jaszcz WB, Gunther R, Nguyen DP, Chelstrom LM, Tuel-Ahlgren L, Uckun FM.
    Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
    [Abstract] [Full Text] [Related]

  • 3. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
    Jansen B, Vallera DA, Jaszcz WB, Nguyen D, Kersey JH.
    Cancer Res; 1992 Mar 01; 52(5):1314-21. PubMed ID: 1371092
    [Abstract] [Full Text] [Related]

  • 4. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Uckun FM, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Manivel C, Irvin JD, Myers DE, Gunther R.
    Blood; 1992 Jun 15; 79(12):3116-29. PubMed ID: 1375841
    [Abstract] [Full Text] [Related]

  • 5. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
    Uckun FM, Manivel C, Arthur D, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Gunther R.
    Blood; 1992 May 01; 79(9):2201-14. PubMed ID: 1373967
    [Abstract] [Full Text] [Related]

  • 6. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin.
    Waurzyniak B, Schneider EA, Tumer N, Yanishevski Y, Gunther R, Chelstrom LM, Wendorf H, Myers DE, Irvin JD, Messinger Y, Ek O, Zeren T, Langlie MC, Evans WE, Uckun FM.
    Clin Cancer Res; 1997 Jun 01; 3(6):881-90. PubMed ID: 9815763
    [Abstract] [Full Text] [Related]

  • 7. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
    Gunther R, Chelstrom LM, Tuel-Ahlgren L, Simon J, Myers DE, Uckun FM.
    Blood; 1995 May 01; 85(9):2537-45. PubMed ID: 7537120
    [Abstract] [Full Text] [Related]

  • 8. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
    Flavell DJ, Boehm DA, Noss A, Warnes SL, Flavell SU.
    Br J Cancer; 2001 Feb 01; 84(4):571-8. PubMed ID: 11207056
    [Abstract] [Full Text] [Related]

  • 9. An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia.
    Myers DE, Uckun FM.
    Leuk Lymphoma; 1995 Jun 01; 18(1-2):119-22. PubMed ID: 8580813
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of HB2 (anti-CD7)--saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice.
    Morland BJ, Barley J, Boehm D, Flavell SU, Ghaleb N, Kohler JA, Okayama K, Wilkins B, Flavell DJ.
    Br J Cancer; 1994 Feb 01; 69(2):279-85. PubMed ID: 7507691
    [Abstract] [Full Text] [Related]

  • 11. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
    Kawata A, Yoshida M, Okazaki M, Yokota S, Barcos M, Seon BK.
    Cancer Res; 1994 May 15; 54(10):2688-94. PubMed ID: 8168098
    [Abstract] [Full Text] [Related]

  • 12. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
    Uckun FM, Myers DE, Irvin JD, Kuebelbeck VM, Finnegan D, Chelstrom LM, Houston LL.
    Leuk Lymphoma; 1993 Apr 15; 9(6):459-76. PubMed ID: 7687916
    [Abstract] [Full Text] [Related]

  • 13. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
    Flavell DJ, Warnes SL, Noss AL, Flavell SU.
    Br J Cancer; 2000 Dec 15; 83(12):1755-61. PubMed ID: 11104577
    [Abstract] [Full Text] [Related]

  • 14. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.
    Flavell DJ, Warnes S, Noss A, Flavell SU.
    Cancer Res; 1998 Dec 15; 58(24):5787-94. PubMed ID: 9865737
    [Abstract] [Full Text] [Related]

  • 15. Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia.
    Ek O, Reaman GH, Crankshaw DL, Chelstrom LM, Myers DE, Uckun FM.
    Leuk Lymphoma; 1998 Feb 15; 28(5-6):509-14. PubMed ID: 9613980
    [Abstract] [Full Text] [Related]

  • 16. Anti-T cell immunotoxins containing pokeweed anti-viral protein: potential purging agents for human autologous bone marrow transplantation.
    Ramakrishnan S, Uckun FM, Houston LL.
    J Immunol; 1985 Nov 15; 135(5):3616-22. PubMed ID: 3900212
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia.
    Fishwild DM, Aberle S, Bernhard SL, Kung AH.
    Cancer Res; 1992 Jun 01; 52(11):3056-62. PubMed ID: 1375534
    [Abstract] [Full Text] [Related]

  • 18. Large scale manufacturing of TXU(anti-CD7)-pokeweed antiviral protein (PAP) immunoconjugate for clinical trials.
    Myers DE, Jun X, Clementson D, Donelson R, Sicheneder A, Hoffman N, Bell K, Sarquis M, Langlie MC, Turner N, Uckun FM.
    Leuk Lymphoma; 1997 Oct 01; 27(3-4):275-302. PubMed ID: 9402326
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA, Halloran PM, Ferris CA, Levine BA, Bourret LA, Goldmacher VS, Blättler WA.
    Cancer Res; 1993 Mar 15; 53(6):1360-7. PubMed ID: 7680284
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.